Status:
COMPLETED
Epigenetic Biomarkers for Alzheimer's Disease
Lead Sponsor:
Chinese University of Hong Kong
Collaborating Sponsors:
Hong Kong University of Science and Technology
Conditions:
Alzheimer Disease
Eligibility:
All Genders
50+ years
Brief Summary
Alzheimer's disease (AD) is a neurodegenerative disorder with no know cure. The pathogenesis of late onset AD (LOAD) is complex and multifactorial in nature, with multiple susceptibility genes and env...
Eligibility Criteria
Inclusion
- Sufficient Cantonese competency for cognitive test
- Written informed consent given
- Have at least one gender-matched cognitively normal sibling
Exclusion
- Subjects who refuse blood taking procedure
- Do not have a reliable family/caregiver informant (personal contact at least once a month)
Key Trial Info
Start Date :
September 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 30 2024
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04081285
Start Date
September 1 2019
End Date
November 30 2024
Last Update
April 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Chinese University of Hong Kong
Hong Kong, Hong Kong